A PROMISE FOR A HEALTHIER TOMORROW

VildaforminF.C.Tablets

Vildaformin
Vildaformin
A recent approach for 24 hours type-2 diabetes control without stimulation of insulin secretion or reduction of glucose levels.
Composition:

Each film coated tablet contains:

  • Vildagliptin 50 mg
  • Metformin hydrochloride 1000 mg.
Propertise:
  • Vildaformin: enhances islet cell insulin secretion via an augmented incretin effect with a high affinity to dipeptidyl peptidase-4 (DPP-4) inhibition that improves glycaemic control.
  • Vildaformin: has a rapid and near complete inhibition of DPP-4 activity with a weak inhibition and rapid dissociation from DPP-8 and DPP-9 compared to DPP-4.
  • Vildaformin: inhibits DPP-4 enzyme activity for 24 hours period that results in increased fasting and post-prandial endogenous levels of incretin hormones GLP-1 (glucagon like peptide-1) and GIP (glucose dependent insulinotropic polypeptide).
  • Vildaformin: enhances the sensitivity of alpha cells to glucose, resulting in reduced glucagon secretion during meals.
  • The increase in the insulin/glucagon ratio with hyperglycaemia due to increased incretin hormone levels, may thus be expected to decrease post-prandial hepatic glucose production so, it leads to glycaemia reducetion.
Dosage & Administration:
  • The dose should be individualised and doses greater than 100 mg are not recommended and may be administered with or without meal. 
  • In dual combination therapy: one tablet once daily in the morning.
  • In combination with insulin: one tablet to be taken once daily.